Zenotech Laboratories

Zenotech Laboratories EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is 151.11. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 45.82 — a change of 229.77% (higher).

EV/FCF

151.11

YoY

229.77%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Zenotech Laboratories is 2026 151.11 . EV/FCF (Enterprise Value to Free Cash Flow) of Zenotech Laboratories was 2025 45.82 . It decreases by 229.77% higher compared to the previous year.

The Zenotech Laboratories EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-9.09 INR
Jan 1, 2020
-29.13 INR
Jan 1, 2021
364.70 INR
Jan 1, 2022
18.30 INR
Jan 1, 2023
19.71 INR
Jan 1, 2024
34.89 INR
Jan 1, 2025
45.82 INR
Jan 1, 2026
151.11 INR
The Zenotech Laboratories EV/FCF history
YEAREV/FCFYoY
151.11+229.77%
45.82+31.34%
34.89+77.01%
19.71+7.69%
18.30-94.98%
364.70-1,351.87%
-29.13+220.57%
-9.09-28.75%
-12.75-103.54%
360.79-616.90%
-69.80+59.97%
-43.63+129.95%
-18.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

EV/FCF (Enterprise Value to Free Cash Flow) of Zenotech Laboratories is 151.11 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Zenotech Laboratories changed from 45.82 to 151.11, representing a 229.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories